Published in AIDS Weekly, August 18th, 1997
The Russian Ministry of Health approved AmBisome, the company's liposomal antifungal drug, as a first line treatment in adults and infants for the treatment of severe systemic fungal infections, including fever of unknown origin (FUO), candidiasis, cryptococcosis, cryptococcal meningitis, aspergillosis, and histoplasmosis. AmBisome now is approved by regulatory authorities for sale in 28 countries throughout the world.
DaunoXome was approved for the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.